Analyst Price Targets — BCYC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 24, 2025 12:33 pm | — | Truist Financial | $10.00 | $6.32 | TheFly | Bicycle Therapeutics initiated with a Hold at Truist |
| October 31, 2025 9:59 am | Reni Benjamin | JMP Securities | $12.00 | $8.76 | TheFly | Bicycle Therapeutics price target raised to $12 from $10 at Citizens JMP |
| October 31, 2025 9:23 am | Leonid Timashev | RBC Capital | $11.00 | $8.76 | TheFly | RBC downgrades Bicycle Therapeutics on slow pipeline progress |
| August 11, 2025 1:08 pm | Leonid Timashev | RBC Capital | $27.00 | $7.59 | TheFly | Bicycle Therapeutics price target raised to $27 from $25 at RBC Capital |
| May 5, 2025 1:40 pm | Maxwell Skor | Morgan Stanley | $17.00 | $9.06 | TheFly | Bicycle Therapeutics price target raised to $17 from $15 at Morgan Stanley |
| December 18, 2024 11:28 am | Reni Benjamin | JMP Securities | $26.00 | $15.32 | TheFly | Bicycle Therapeutics price target lowered to $26 from $32 at JMP Securities |
| October 24, 2024 6:37 am | Jay Olson | Oppenheimer | $48.00 | $25.32 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Bicycle Therapeutics (BCYC) |
| October 24, 2024 6:32 am | Kalpit Patel | B.Riley Financial | $28.00 | $25.32 | StreetInsider | B.Riley Reiterates Neutral Rating on Bicycle Therapeutics (BCYC) |
| September 16, 2024 7:08 am | Swayampakula Ramakanth | H.C. Wainwright | $55.00 | $27.02 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Bicycle Therapeutics (BCYC) |
| October 7, 2021 12:00 am | Anthony Butler | Roth Capital | $65.00 | $48.69 | StreetInsider | Bicycle Therapeutics (BCYC) PT Raised to $65 at Roth Capital |
Latest News for BCYC
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have given a buy recommendation to the
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced leadership transitions for its next phase of innovation. Travis Thompson, who began at Bicycle in April 2018 and most recently served as Bicycle's senior vice president…
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today highlights 2025 accomplishments and strategic priorities for 2026. "In 2025, we remained steadfast in our goal of helping patients live longer and live well, making meaningful…
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating on the
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA) for access to up to 400 tonnes of reprocessed…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BCYC.
U.S. House Trading
No House trades found for BCYC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.